Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DCGO DocGo	$1.40 +0.9%	$1.53	$1.23 ▼ $5.68	$142.26M	0.97	917,329 shs	30,666 shs
EUDA EUDA Health	$3.37 +2.4%	$3.58	$2.92 ▼ $6.30	$125.23M	-0.04	83,853 shs	54,716 shs
OPGN OpGen	$4.60 +13.6%	$4.78	$0.53 ▼ $5.25	$46.31M	-1.66	8,971 shs	1,319 shs
XGN Exagen	$6.94 +2.3%	$6.79	$1.78 ▼ $7.95	$147.72M	1.58	199,903 shs	2,570 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DCGO DocGo	-4.79%	-10.32%	-4.14%	-36.53%	-55.31%
EUDA EUDA Health	-1.82%	-3.58%	-12.94%	-18.84%	-15.45%
OPGN OpGen	-15.27%	-17.85%	-18.02%	-1.22%	+32.35%
XGN Exagen	-4.10%	-2.45%	-4.78%	+51.68%	+242.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DCGO DocGo	2.1774 of 5 stars	3.3	1.0	0.0	0.0	2.7	2.5	0.6
EUDA EUDA Health	1.2558 of 5 stars	0.0	5.0	0.0	0.0	3.3	0.0	0.6
OPGN OpGen	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XGN Exagen	3.8922 of 5 stars	2.5	2.0	0.0	4.5	3.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DCGO DocGo	2.50	Moderate Buy	$3.56	156.12% Upside
EUDA EUDA Health	4.00	Strong Buy	N/A	N/A
OPGN OpGen	0.00	N/A	N/A	N/A
XGN Exagen	3.00	Buy	$7.50	10.62% Upside

Current Analyst Ratings Breakdown

Latest OPGN, DCGO, XGN, and EUDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	XGN Exagen	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/15/2025	XGN Exagen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$8.00 ➝ $7.00
5/13/2025	XGN Exagen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/12/2025	DCGO DocGo	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$5.00 ➝ $1.45
5/9/2025	DCGO DocGo	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
5/9/2025	DCGO DocGo	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/7/2025	XGN Exagen	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DCGO DocGo	$616.55M	0.23	$0.40 per share	3.45	$3.09 per share	0.45
EUDA EUDA Health	$4.01M	29.93	N/A	N/A	($0.07) per share	-46.14
OPGN OpGen	$2.67M	15.25	N/A	N/A	($11.55) per share	-0.35
XGN Exagen	$55.64M	2.60	N/A	N/A	$0.54 per share	12.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DCGO DocGo	$19.99M	-$0.02	N/A	17.38	N/A	-0.12%	2.52%	1.70%	8/6/2025 (Estimated)
EUDA EUDA Health	-$15.36M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
OPGN OpGen	-$32.67M	N/A	0.00	∞	N/A	-1,140.36%	N/A	-287.58%	N/A
XGN Exagen	-$15.11M	-$0.84	N/A	N/A	N/A	-27.34%	-133.69%	-34.87%	8/4/2025 (Estimated)

Latest OPGN, DCGO, XGN, and EUDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	DCGO DocGo	-$0.06	N/A	N/A	N/A	$77.58 million	N/A
8/4/2025	Q2 2025	XGN Exagen	-$0.18	N/A	N/A	N/A	$16.25 million	N/A
7/29/2025	N/A	EUDA EUDA Health	-$0.02	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	XGN Exagen	-$0.20	-$0.20	N/A	-$0.20	$14.55 million	$15.50 million
5/8/2025	Q1 2025	DCGO DocGo	-$0.01	-$0.09	-$0.08	-$0.09	$104.25 million	$96.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DCGO DocGo	N/A	N/A	N/A	N/A	N/A
EUDA EUDA Health	N/A	N/A	N/A	N/A	N/A
OPGN OpGen	N/A	N/A	N/A	N/A	N/A
XGN Exagen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DCGO DocGo	N/A	2.44	2.44
EUDA EUDA Health	N/A	0.18	0.15
OPGN OpGen	N/A	5.45	5.45
XGN Exagen	2.87	2.32	2.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DCGO DocGo	56.44%
EUDA EUDA Health	4.35%
OPGN OpGen	2.68%
XGN Exagen	75.25%

Insider Ownership

Company	Insider Ownership
DCGO DocGo	2.70%
EUDA EUDA Health	N/A
OPGN OpGen	43.80%
XGN Exagen	12.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DCGO DocGo	4,407	101.98 million	99.23 million	Optionable
EUDA EUDA Health	2	37.16 million	N/A	Not Optionable
OPGN OpGen	100	10.07 million	4.70 million	Not Optionable
XGN Exagen	220	21.30 million	18.62 million	Optionable

OPGN, DCGO, XGN, and EUDA Headlines

Recent News About These Companies

Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025

July 15 at 4:32 PM | globenewswire.com

Exagen Insider Ups Holding During Year

June 29, 2025 | finance.yahoo.com

2025-06-23 | Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics | NDAQ:XGN | Press Release - Stockhouse

June 24, 2025 | stockhouse.com

Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

June 23, 2025 | globenewswire.com

Exagen announces resale of up to 1.15M shares

June 20, 2025 | msn.com

Exagen Inc. Holds 2025 Annual Stockholder Meeting

June 11, 2025 | tipranks.com

Exagen Inc. (NASDAQ:XGN) Q1 2025 Earnings Call Transcript

May 11, 2025 | insidermonkey.com

Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

May 9, 2025 | finance.yahoo.com

Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

May 9, 2025 | globenewswire.com

Exagen Inc. Prices Public Offering of Common Stock

May 8, 2025 | globenewswire.com

KeyBanc maintains Exagen stock at Sector Weight

May 7, 2025 | investing.com

KeyBanc maintains Exagen stock at Sector Weight

May 7, 2025 | investing.com

Exagen Inc. Announces Proposed Public Offering of Common Stock

May 7, 2025 | globenewswire.com

Earnings call transcript: Exagen Inc. Q1 2025 revenue beats forecasts, stock dips

May 6, 2025 | uk.investing.com

Exagen Inc. Reports Record Revenue Amid Strategic Growth

May 5, 2025 | tipranks.com

Exagen Inc. Earnings Call Highlights Record Growth

May 5, 2025 | tipranks.com

Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript

May 5, 2025 | seekingalpha.com

Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates

May 5, 2025 | zacks.com

Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

May 5, 2025 | globenewswire.com

Exagen Inc (XGN) Q1 2025 Earnings Report Preview: What To Expect

May 3, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPGN, DCGO, XGN, and EUDA Company Descriptions

DocGo NASDAQ:DCGO

$1.40 +0.01 (+0.94%)

As of 10:19 AM Eastern

DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.

EUDA Health NASDAQ:EUDA

$3.37 +0.08 (+2.43%)

As of 10:17 AM Eastern

EUDA Health Holdings Limited operates as a healthcare specialty company. The company operates through two segments, Medical Services and Property Management Services. It offers a range of specialty care services to patients; and operates medical facility general practice clinic that provides holistic care for various illnesses. The company is also involved in the property management that services shopping malls, business office building, or residential apartments. EUDA Health Holdings Limited is headquartered in Singapore.

OpGen NASDAQ:OPGN

$4.60 +0.55 (+13.58%)

As of 09:57 AM Eastern

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

Exagen NASDAQ:XGN

$6.94 +0.16 (+2.29%)

As of 10:19 AM Eastern

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time